EcoDrugPlus

Nfe2 Like Bzip Transcription Factor 2a

Ensembl ID : ENSDLAG00005004683
Gene Symbol: NFE2L2A
1 Cross references
205 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSDLAG00005025320
Gene Symbol: NAMPT
1 Cross references
220 Possible Orthologues:

Notch Receptor 1b

Ensembl ID : ENSDLAG00005003503
Gene Symbol: NOTCH1B
1 Cross references
200 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSDLAG00005016757
Gene Symbol: NOTCH3
1 Cross references
194 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSDLAG00005022607
Gene Symbol: NR1H3
1 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 4

Ensembl ID : ENSDLAG00005023155
Gene Symbol: NR1H4
1 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSDLAG00005007724
Gene Symbol: NR3C1
1 Cross references
206 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSDLAG00005005166
Gene Symbol: NR3C1
1 Cross references
207 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSDLAG00005018936
Gene Symbol: NR3C2
1 Cross references
209 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSDLAG00005024955
Gene Symbol: NOD2
1 Cross references
167 Possible Orthologues:

Opioid Receptor, Delta 1b

Ensembl ID : ENSDLAG00005017954
Gene Symbol: OPRD1B
1 Cross references
178 Possible Orthologues:

Opioid Receptor, Kappa 1

Ensembl ID : ENSDLAG00005021950
Gene Symbol: OPRK1
1 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).